Prospera Financial Services Inc Purchases Shares of 4,640 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Prospera Financial Services Inc purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Rating) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 4,640 shares of the company’s stock, valued at approximately $172,000.

Several other institutional investors have also added to or reduced their stakes in IONS. Millennium Management LLC boosted its position in Ionis Pharmaceuticals by 473.8% during the 4th quarter. Millennium Management LLC now owns 1,623,138 shares of the company’s stock valued at $49,392,000 after buying an additional 1,340,284 shares during the period. Bellevue Group AG raised its holdings in Ionis Pharmaceuticals by 10.8% in the 4th quarter. Bellevue Group AG now owns 10,355,123 shares of the company’s stock worth $315,106,000 after purchasing an additional 1,007,197 shares in the last quarter. Sio Capital Management LLC bought a new position in Ionis Pharmaceuticals in the 4th quarter worth $9,816,000. TD Asset Management Inc. raised its holdings in Ionis Pharmaceuticals by 76.1% in the 4th quarter. TD Asset Management Inc. now owns 743,164 shares of the company’s stock worth $22,614,000 after purchasing an additional 321,200 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Ionis Pharmaceuticals by 639.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 357,896 shares of the company’s stock worth $13,256,000 after purchasing an additional 309,495 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Ionis Pharmaceuticals Stock Up 10.3 %

NASDAQ:IONS opened at $41.02 on Thursday. The firm has a market cap of $5.82 billion, a P/E ratio of -205.09 and a beta of 0.70. The company has a debt-to-equity ratio of 1.76, a quick ratio of 9.76 and a current ratio of 9.86. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $25.04 and a fifty-two week high of $44.42. The firm has a 50-day simple moving average of $37.09 and a two-hundred day simple moving average of $35.98.

Ionis Pharmaceuticals (NASDAQ:IONSGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.22. The business had revenue of $142.00 million during the quarter, compared to analyst estimates of $122.46 million. Ionis Pharmaceuticals had a negative net margin of 0.36% and a negative return on equity of 0.46%. Ionis Pharmaceuticals’s revenue was up 26.8% compared to the same quarter last year. During the same period last year, the business earned ($0.64) EPS. Analysts predict that Ionis Pharmaceuticals, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. TheStreet lowered shares of Ionis Pharmaceuticals from a “c-” rating to a “d” rating in a report on Monday, June 6th. Oppenheimer restated an “outperform” rating and issued a $59.00 price objective on shares of Ionis Pharmaceuticals in a report on Monday, July 18th. SVB Leerink upped their price objective on shares of Ionis Pharmaceuticals from $26.00 to $27.00 and gave the stock a “market perform” rating in a report on Tuesday, June 21st. StockNews.com lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 13th. Finally, Piper Sandler increased their price target on shares of Ionis Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 26th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $45.30.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Joseph Klein III sold 1,333 shares of the firm’s stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $38.24, for a total transaction of $50,973.92. Following the completion of the sale, the director now directly owns 18,791 shares in the company, valued at approximately $718,567.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.36% of the stock is owned by company insiders.

About Ionis Pharmaceuticals

(Get Rating)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

Featured Articles

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Rating).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.